Acasă › Leucemie mieloasă acută › Oregon
Studii clinice pentru Leucemie mieloasă acută în Oregon
27 studii pentru Leucemie mieloasă acută caută participanți în Oregon.
Orașe în Oregon
Text oficial al studiului (în engleză)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- și încă 7
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
Vârste de la 40 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
În curs de recrutareFaza 2
Vârste de la 18 la 59 · Toate sexele · Actualizat 28 sept. 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT05564390Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT03874052Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
În curs de recrutareFaza 2
Vârste de la 18 la 59 · Toate sexele · Actualizat 22 sept. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
În curs de recrutareFaza 3
6 Months – 21 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Oregon Health & Science University, Portland
În curs de recrutareFaza 1/2
30 Days · Toate sexele · Actualizat 16 sept. 2026 · NCT04065399Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- OHSU Knight Cancer Institute, Portland
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 16 sept. 2026 · NCT06504459Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Oregon Health and Science University, Portland
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT03471260Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Portland OR-OHSU, Portland
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 sept. 2026 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
În curs de recrutareFaza 1/2
Până la vârsta de 22 · Toate sexele · Actualizat 25 aug. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Doernbecher Children's Hospital, Portland
În curs de recrutareFaza 3
29 Days – 21 Years · Toate sexele · Actualizat 24 aug. 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Willamette Valley Cancer Institute, Eugene
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 20 aug. 2026 · NCT07007312Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
În curs de recrutareFaza 3
Vârste de la 18 la 75 · Toate sexele · Actualizat 17 iul. 2026 · NCT05429632Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 14 iul. 2026 · NCT04659616Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
În curs de recrutareFaza 2
Vârste de la 18 la 65 · Toate sexele · Actualizat 13 iul. 2026 · NCT07228273Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 7 iul. 2026 · NCT07216443Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
- OHSU Knight Cancer Institute, Portland
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 6 iul. 2026 · NCT07548983A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Oregon Health & Science University/Doernbecher Children's Hospital, Portland
În curs de recrutareStudiu observațional
Toate vârstele · Toate sexele · Actualizat 6 iul. 2026 · NCT01351545Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 30 iun. 2026 · NCT06357182A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Oregon Health and Science University, Portland
- Oregon Oncology Specialists, Salem
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 30 apr. 2026 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Oncology Associates of Oregon, Eugene
În curs de recrutareFaza 1/2
Vârste de 12 ani și peste · Toate sexele · Actualizat 24 mar. 2026 · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Oregon Health & Science University, Portland
În curs de recrutareFaza 2
Vârste de la 18 la 66 · Toate sexele · Actualizat 17 mar. 2026 · NCT06859424A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- OHSU, Portland
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 9 feb. 2026 · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Oregon Health & Science University, Portland
În curs de recrutareVoluntari sănătoși bineveniți
Vârste de la 18 la 120 · Toate sexele · Actualizat 25 iul. 2025 · NCT05237258Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.